Lucid Diagnostics Provides Business Update and Fourth Quarter and Full Year 2022 Financial Results

4Q22 and projected 1Q23 EsoGuard® test volume increases 8 and 36 percent sequentially and 288 and 300 percent annually. Company signs in-network agreement with largest secondary PPO, MultiPlan, expanding patient access to EsoGuard. Company secures financing of $24.6 million through…

Leave a Reply

Your email address will not be published. Required fields are marked *